" class="no-js "lang="en-US"> Scott Solomon - Medtech Alert
Saturday, December 14, 2024
Scott Solomon

Scott Solomon

About Scott Solomon

Related Story

Farxiga Met Primary Endpoint in DELIVER Phase III Trial, Reducing Risk of Cardiovascular Death or Worsening Heart Failure in Patients with Preserved Ejection Fraction

May 6 2022

High-level results from the DELIVER Phase III trial showed AstraZeneca’s Farxiga (dapagliflozin) reached a statistically […]